Publication:
Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria

dc.contributor.authorJames Watsonen_US
dc.contributor.authorWalter R.J. Tayloren_US
dc.contributor.authorGermana Banconeen_US
dc.contributor.authorCindy S. Chuen_US
dc.contributor.authorPodjanee Jittamalaen_US
dc.contributor.authorNicholas J. Whiteen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherNuffield Department of Clinical Medicineen_US
dc.date.accessioned2019-08-28T06:13:27Z
dc.date.available2019-08-28T06:13:27Z
dc.date.issued2018-04-20en_US
dc.description.abstract© 2018 Watson et al. Background: The 8-aminoquinoline antimalarials, the only drugs which prevent relapse of vivax and ovale malaria (radical cure), cause dose-dependent oxidant haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Patients with <30% and <70% of normal G6PD activity are not given standard regimens of primaquine and tafenoquine, respectively. Both drugs are currently considered contraindicated in pregnant and lactating women. Methods: Quantitative G6PD enzyme activity data from 5198 individuals were used to estimate the proportions of heterozygous females who would be ineligible for treatment at the 30% and 70% activity thresholds, and the relationship with the severity of the deficiency. This was used to construct a simple model relating allele frequency in males to the potential population coverage of tafenoquine and primaquine under current prescribing restrictions. Findings: Independent of G6PD deficiency, the current pregnancy and lactation restrictions will exclude ~13% of females from radical cure treatment. This could be reduced to ~4% if 8-aminoquinolines can be prescribed to women breast-feeding infants older than 1 month. At a 30% activity threshold, approximately 8–19% of G6PD heterozygous women are ineligible for primaquine treatment; at a 70% threshold, 50–70% of heterozygous women and approximately 5% of G6PD wild type individuals are ineligible for tafenoquine treatment. Thus, overall in areas where the G6PDd allele frequency is >10% more than 15% of men and more than 25% of women would be unable to receive tafenoquine. In vivax malaria infected patients these proportions will be lowered by any protective effect against P. vivax conferred by G6PD deficiency. Conclusion: If tafenoquine is deployed for radical cure, primaquine will still be needed to obtain high population coverage. Better radical cure antimalarial regimens are needed.en_US
dc.identifier.citationPLoS Neglected Tropical Diseases. Vol.12, No.4 (2018)en_US
dc.identifier.doi10.1371/journal.pntd.0006440en_US
dc.identifier.issn19352735en_US
dc.identifier.issn19352727en_US
dc.identifier.other2-s2.0-85046340522en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/46750
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85046340522&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleImplications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malariaen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85046340522&origin=inwarden_US

Files

Collections